All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Frontline Ribociclib/Endocrine Therapy Generates Similar ORR to Combination Chemo in HR+/HER2– Advanced Breast Cancer

February 27th 2023

Yen-Shen Lu, MD, PhD, discusses the primary results of the RIGHT Choice trial and what they could mean for the use of ribociclib and endocrine therapy in this population.

Three Talented Researchers Recognized as Endowed Chairs

February 27th 2023

Huntsman Cancer Institute at the University of Utah congratulates three of their newest endowed chairs.

FDA Grants Priority Review to Nirogacestat for Desmoid Tumors

February 27th 2023

The FDA has granted a priority review to the new drug application for nirogacestat for the treatment of adult patients with desmoid tumors.

Triplet Regimen for Microsatellite Stable, BRAF V600E–Mutant mCRC Aims to Build Upon SOC

February 27th 2023

Because a positive correlation has been shown between expression of PD-L1 and BRAF V600E mutations in CRC, several combination therapies with checkpoint inhibitors and targeted agents are currently being explored.

Tislelizumab Plus Chemo Approved in China for PD-L1–High Advanced Gastric/GEJ Adenocarcinoma

February 27th 2023

The National Medical Products Administration of China has granted approval to tislelizumab in combination with fluoropyrimidine and platinum chemotherapy in the frontline treatment of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma with a high PD-L1 expression.

Lenvatinib Plus Pembrolizumab Generates Durable Responses in Advanced Endometrial Carcinoma

February 26th 2023

Lenvatinib in combination with pembrolizumab led to deep and durable tumor responses in patients with previously treated advanced endometrial carcinoma.

Davids Highlights Mounting Treatment Options in CLL

February 25th 2023

Patients with chronic lymphocytic leukemia, including those with difficult-to-treat disease classes such as double refractory, are quickly gaining more effective treatment options.

Liquid Biopsies and NGS Stand to Revolutionize Hematologic Malignancies

February 24th 2023

Andrew Ip, MD, delivers a keynote on the role for liquid biopsy and NGS in hematologic malignancies, including the barriers to implementing seamlessly into clinical practice.

Trastuzumab Deruxtecan Garners Approval in China for HER2+ Metastatic Breast Cancer

February 24th 2023

The National Medical Products Administration of China has approved the use of single-agent fam-trastuzumab deruxtecan-nxki in adult patients with unresectable or metastatic HER2-positive breast cancer who previously received 1 or more anti–HER2-based regimens.

Real-World Analysis May Clarify Role of Adjuvant Endocrine Therapy in Premenopausal HER2+ Breast Cancer

February 24th 2023

Jasmine Sukumar, MD, discusses the purpose of analyzing endocrine therapy use in HR-positive/HER2-positive patients, key data presented from the retrospective analysis at SABCS, and the need for improved understanding of clinical indications for endocrine therapy in this breast cancer subtype.

AR Pathway Inhibitors, ADCs, and IO/TKI Combinations Shape Standard Therapy in GU Cancers

February 24th 2023

Chandler Park, MD, MSc, FACP, discusses the evolution of metastatic hormone-sensitive prostate cancer treatment, shifting definitions of metastatic and nonmetastatic castration-resistant prostate cancer, the importance of antibody-drug conjugates in bladder cancer, and the future of biomarkers in renal cell carcinoma.

Baptist Health Miami Cancer Institute Celebrates 1000th Patient Treated Using Gamma Knife

February 24th 2023

Baptist Health Miami Cancer Institute treated its 1000th patient using Gamma Knife radiosurgery, an incisionless radiation therapy that precisely targets a tumor, importantly minimizing damage to otherwise healthy brain tissue.

Cemiplimab Plus Chemotherapy Approaches EU Approval for PD-L1+ NSCLC

February 24th 2023

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of cemiplimab-rwlc in combination with platinum-based chemotherapy as frontline treatment for adult patients with advanced non–small cell lung cancer with PD-L1 expression of 1% or higher.

Finding and Leveraging CEACAM5 Presents Opportunities and Pitfalls

February 24th 2023

As carcinoembryonic antigen–related cell adhesion molecule 5 continues to show promise a target in patients with non–small cell lung cancer, refinements in testing and the understanding of the implications of its inhibition remain under investigation.

Bevacizumab Plus TAS-102 Elicits Survival Improvements in Third-line mCRC

February 24th 2023

Bevacizumab plus trifluridine/tipiracil demonstrated improved overall survival and progression-free survival vs TAS-102 alone as third-line treatment for patients with refractory metastatic colorectal cancer.

Bria-IMT Plus Retifanlimab Continues to Show Early Clinical Benefit in Advanced Metastatic Breast Cancer

February 23rd 2023

The combination of the targeted immunotherapy Bria-IMT and retifanlimab demonstrated signs of clinical benefit and was found to be well tolerated in patients with advanced metastatic breast cancer.

Abatacept/Ruxolitinib May Reduce Cardiotoxicity Associated With Immune Checkpoint Inhibitors

February 23rd 2023

French investigators evaluated a potential solution to reduce myotoxicity and improve survival for patients with cancer receiving treatment with immune checkpoint inhibitors.

Patients With Brain Cancer May Benefit From Treatment to Boost White Blood Cells

February 23rd 2023

A new study led by Washington University School of Medicine in St. Louis reveals at least one cause of low white blood cells.

Investigational Treatments for Refractory RCC Expand Beyond Immunotherapy

February 23rd 2023

Brian I. Rini, MD, discusses standard and investigational treatment options for patients with RCC who are refractory to immunotherapy; the potential role of biomarkers in future targeted treatments; and the need for novel mechanisms such as HIF inhibition to meet the needs of patients who don’t respond to immunotherapy or VEGF TKIs.

FDA Grants Breakthrough Therapy Designation to mRNA-4157/V940 Plus Pembrolizumab in High-Risk Melanoma

February 23rd 2023

The FDA has granted a breakthrough therapy designation to the investigational personalized mRNA cancer vaccine mRNA-4157/V940 in combination with pembrolizumab for the adjuvant treatment of patients with high-risk melanoma following complete resection.